Equities

MDxHealth SA

MDXH:NAQ

MDxHealth SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.75
  • Today's Change0.02 / 0.73%
  • Shares traded9.56k
  • 1 Year change-24.45%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

  • Revenue in USD (TTM)75.33m
  • Net income in USD-39.90m
  • Incorporated2003
  • Employees300.00
  • Location
    MDxHealth SACAP Business Center, Rue d'Abhooz 31HERSTAL 4040BelgiumBEL
  • Phone+32 43642070
  • Fax+32 42597875
  • Websitehttps://mdxhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Provectus Biopharmaceuticals Inc590.75k-2.78m71.32m4.00------120.73-0.0066-0.00660.0014-0.01780.4221--1,358.05147,687.50-198.50-276.33---------470.31-1,667.76---10.24-----43.61--12.74------
Benitec Biopharma Inc7.00k-21.69m71.66m18.00--1.81--10,237.32-9.87-9.870.00314.220.0006--0.1284388.89-186.85-83.43-260.89-98.771,542.8696.86-309,885.70-468.04---307.030.00--2.74-53.84-7.44---56.51--
Alpha Teknova Inc36.85m-36.06m71.85m210.00--0.8617--1.95-1.05-1.051.052.040.28152.297.89175,490.50-27.54---29.30--27.36---97.85--3.92-28.230.1365---11.43--22.52------
Bioatla Inc0.00-119.24m72.66m65.00--1.46-----2.49-2.490.001.030.00----0.00-81.18-48.72-96.07-57.35-------6,651.71----0.00-------15.95---37.01--
Annovis Bio Inc0.00-47.53m73.17m6.00---------5.04-5.040.00-0.30460.00----0.00-284.97-106.31-411.92-124.71-----------9.20---------121.90------
Aclaris Therapeutics Inc31.12m-77.26m73.40m91.00--0.5168--2.36-1.09-1.090.43921.990.1541--58.77341,967.00-38.27-47.29-42.29-53.8741.9944.00-248.28-549.18----0.00--5.0338.41-1.81---0.703--
Tempest Therapeutics Inc0.00-29.76m73.76m17.00--3.58-----1.76-1.760.000.92870.00----0.00-72.84-57.10-93.72-71.20-----------141.390.3394------17.41--36.40--
MDxHealth SA - ADR75.33m-39.90m75.04m300.00------0.9962-1.14-1.140.8428-0.03570.552811.066.95251,090.00-29.28-51.62-33.98-64.7262.7650.88-52.97-117.641.53-1.541.02--89.4319.842.14--30.13--
Bakhu Holdings Corp0.00-1.92m75.33m2.00---------0.0064-0.00640.00-0.03250.00----0.00-281.75-4,391.82---------------8.39--------33.37------
Spero Therapeutics Inc110.98m23.40m76.66m46.003.370.79483.240.69080.42130.42132.081.790.792--3.962,412,565.0016.70-35.5221.73-41.75----21.09-124.40----0.00--93.9592.11149.14------
Anixa Biosciences Inc210.00k-10.74m77.52m4.00--3.14--369.13-0.3451-0.34510.00680.77490.0078--0.780752,500.00-40.49-59.69-41.26-62.61-----5,174.29-6,040.10----0.00-----28.3627.83------
IO Biotech Inc0.00-88.50m77.74m68.00--0.6733-----1.86-1.860.001.750.00----0.00-66.79---72.66--------------0.00-------20.47------
Marinus Pharmaceuticals Inc28.29m-145.34m78.01m165.00------2.76-2.64-2.640.5142-0.29920.15540.85363.72171,442.40-79.82-49.64-96.93-57.7691.22---513.80-518.962.93-13.621.29--21.63---613.59--7.47--
Cognition Therapeutics Inc0.00-28.77m78.11m25.00--2.70-----0.9155-0.91550.000.72180.00----0.00-68.08---85.18-------------251.590.00-------20.52------
Elutia Inc25.05m-49.46m79.14m54.00------3.16-2.35-2.341.24-2.070.52192.064.27463,833.30-103.05-42.93-599.50-79.3442.0143.32-197.48-64.160.5499-1.36-----49.69-8.71-25.39--12.74--
Data as of May 31 2024. Currency figures normalised to MDxHealth SA's reporting currency: US Dollar USD

Institutional shareholders

2.62%Per cent of shares held by top holders
HolderShares% Held
Bleichroeder LPas of 31 Dec 2022420.00k1.54%
BNP Paribas Asset Management Belgium SAas of 30 Apr 2024136.18k0.50%
OneDigital Investment Advisors LLCas of 31 Mar 202440.70k0.15%
Hood River Capital Management LLCas of 31 Dec 202337.64k0.14%
Perkins Capital Management, Inc.as of 31 Dec 202335.00k0.13%
XTX Markets LLCas of 31 Mar 202419.73k0.07%
FAS Wealth Partners, Inc.as of 31 Mar 202416.33k0.06%
Geode Capital Management LLCas of 31 Mar 20245.26k0.02%
UBS Securities LLCas of 31 Mar 20241.60k0.01%
Dimensional Fund Advisors Ltd.as of 31 Mar 20241.27k0.01%
More ▼
Data from 31 Mar 2024 - 23 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.